AbbVie Inc. (ABBV) 10-K Red Flags
Risk signals extracted deterministically from AbbVie Inc.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (8)
- Operating cash flow exceeds net income: OCF is 4.50x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Market cap $457.54B at $258.92 per share.
- Trailing P/E 109.71, P/S 7.48.
- Composite risk: Elevated.
- Leverage debt/equity -10.87 (low).
Filings & ownership
- Latest annual report (10-K) filed Feb 20, 2026.
- Latest quarterly report (10-Q) filed Aug 3, 2026.
- 20 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference AbbVie Inc.; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., K2 PRINCIPAL FUND, L.P., Saranac Partners Ltd.
- 1 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 19 recent 13G passive institutional ownership notices.
Full ABBV analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.